Harigai M - Search Results

1

A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: The ACTEMRA® (ACT)-Bridge study.

Harigai M, Miyamae T, Hashimoto H, Yoshida A, Yamashita K, Nakaoka Y. Harigai M, et al. Mod Rheumatol. 2023 Aug 25;33(5):998-1006. doi: 10.1093/mr/roac099. Mod Rheumatol. 2023. PMID: 36057089

2

A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis.

Kobayashi S, Harigai M, Mozaffarian N, Pangan AL, Sharma S, Brown LS, Miyasaka N. Kobayashi S, et al. Among authors: harigai m. Mod Rheumatol. 2012 Aug;22(4):589-97. doi: 10.1007/s10165-011-0557-x. Epub 2011 Dec 29. Mod Rheumatol. 2012. PMID: 22205117 Free PMC article. Clinical Trial.

3

A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology.

Takamura A, Hirata S, Nagasawa H, Kameda H, Seto Y, Atsumi T, Dohi M, Koike T, Miyasaka N, Harigai M. Takamura A, et al. Among authors: harigai m. Mod Rheumatol. 2013 Mar;23(2):297-303. doi: 10.1007/s10165-012-0658-1. Epub 2012 May 10. Mod Rheumatol. 2013. PMID: 22572888

4

Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.

Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yaguramaki H, Yamanaka H. Koike T, et al. Among authors: harigai m. J Rheumatol. 2014 Jan;41(1):15-23. doi: 10.3899/jrheum.130466. Epub 2013 Nov 1. J Rheumatol. 2014. PMID: 24187110 Free article.

5

Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis.

Takeuchi T, Kawai S, Yamamoto K, Harigai M, Ishida K, Miyasaka N. Takeuchi T, et al. Among authors: harigai m. Mod Rheumatol. 2014 Jan;24(1):8-16. doi: 10.3109/14397595.2013.854074. Mod Rheumatol. 2014. PMID: 24261753

6

A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan.

Cho SK, Sakai R, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Tanaka Y, Nakajima A, Yasuda S, Ihata A, Ezawa K, Won S, Choi CB, Sung YK, Kim TH, Jun JB, Yoo DH, Miyasaka N, Bae SC, Harigai M; RESEARCH investigators; REAL Study Group. Cho SK, et al. Among authors: harigai m. Mod Rheumatol. 2014 Jul;24(4):572-9. doi: 10.3109/14397595.2013.860695. Epub 2013 Dec 9. Mod Rheumatol. 2014. PMID: 24320747

7

Trend of patient characteristics and its impact on the response to adalimumab in patients with rheumatoid arthritis: post hoc time-course analysis of an all-case PMS in Japan.

Yamanaka H, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, Tanaka Y, Suzuki H, Shinmura Y, Koike T. Yamanaka H, et al. Among authors: harigai m. Mod Rheumatol. 2015 Jul;25(4):495-502. doi: 10.3109/14397595.2014.994263. Epub 2015 Jan 13. Mod Rheumatol. 2015. PMID: 25487291

8

Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study.

Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Ishii Y, Nakajima H, Baker D, Miyasaka N, Koike T. Tanaka Y, et al. Among authors: harigai m. Mod Rheumatol. 2016;26(3):323-30. doi: 10.3109/14397595.2015.1086041. Epub 2015 Oct 16. Mod Rheumatol. 2016. PMID: 26471830 Clinical Trial.

9

High prevalence of cardiovascular comorbidities in patients with rheumatoid arthritis from a population-based cross-sectional study of a Japanese health insurance database.

Sakai R, Hirano F, Kihara M, Yokoyama W, Yamazaki H, Harada S, Nanki T, Koike R, Miyasaka N, Harigai M. Sakai R, et al. Among authors: harigai m. Mod Rheumatol. 2016 Jul;26(4):522-8. doi: 10.3109/14397595.2015.1106682. Epub 2015 Dec 14. Mod Rheumatol. 2016. PMID: 26666766

10

Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.

Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y, Sakai R, Yamazaki H, Koike T, Miyasaka N. Harigai M, et al. Mod Rheumatol. 2016 Sep;26(5):642-50. doi: 10.3109/14397595.2016.1141740. Epub 2016 Mar 11. Mod Rheumatol. 2016. PMID: 26873430

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

421 results

Search Page

Filters